Fixed-combination halobetasol propionate and tazarotene topical lotion decreases TNF-α and IL-17A levels in psoriatic lesions

• मुख्य लेखकों: Zoe Diana Draelos (लेखक), Matthew M. Draelos (लेखक), Tina Lin (लेखक), Abby Jacobson (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Objective Fixed-combination halobetasol propionate (0.01%) and tazarotene (0.045%) lotion (HP/TAZ) is approved for the treatment of plaque psoriasis in adults, with a demonstrated efficacy and safety profile in phase 3 trials. This study examined the effect of HP/TAZ on the reduction of tumor necros...